This study expands the role of NRF2 as a key element in driving drug resistance and opens up a novel strategy of sensitising cancer cells to HER2 targeted therapy, as well as overcoming the resistance of cancer cells to such immunotherapeutics. This evidence concerns the gene NFE2L2 and cancer.